MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
3. Government_Funders & Regulators
*Government: International
Europe
*Europe: Regions
*Western Europe
Ireland
*Industry: Ireland
Alkermes plc (NASDAQ:ALKS)
Organization & Developments: Alkermes
Parents
Alkermes plc (NASDAQ:ALKS)
Children
*DEVELOPS THERAPIES BASED ON PROPRIETARY DRUG DELIVERY TECHNOLOGY TO ENHANCE EXISTING DRUGS
2018: Alkermes Depression Drug Faces Long Odds After FDA Advisors Say No
2018: Alkermes: A Solid CNS Portfolio With An Option For Depression - Alkermes plc (NASDAQ:ALKS)
2018: FDA Refuses Review of Alkermes Depression Drug, Wants More Trials
2018: FDA rejects Alkermes' marketing application for MDD med ALKS 5461_seekingalpha.com
2018: In a stunning about face, the FDA is now welcoming the new drug application from Alkermes it rejected 2 weeks ago – Endpoints News
2018: VA_65--Alkermes, Inc 08/01/2018
2019: Alkermes (NASDAQ: ALKS), Revisting Before Upcoming ALKS-4230 Immuno-Oncology Data_seekingalpha.com
2019: Alkermes Eyes Brain Disorders and Beyond With $100M Deal for Rodin
2019: Alkermes: It Takes More_seekingalpha.com
2019: Alkermes: Offering A Speculative Entry Point_seekingalpha.com
2019: As shares suffer from a lingering slump, a bruised Alkermes slashes 160 jobs in R&D restructuring – Endpoints News
2020: Alkermes is handed a CRL for ‘3831, marking another setback on the R&D front
2022: Alkermes plc 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Alkermes: Nothing Stands Out As Interesting_ seekingalpha.com
2023: Alkermes' OX2R Agonist For Narcolepsy Peaks Interest Amidst Strong Q3 Earnings
2024: Alkermes Eyes Completion of Phase 2 Narcolepsy Studies in 2025
2024: Alkermes plc 2023 Q4 - Results - Earnings Call Presentation
2024: Alkermes: Additional Narcolepsy Data Could Lead The Way To The Next Stage
2024: Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth
2024: Alkermes: Slimmed-Down Pharma Not A Compelling Growth Story Yet
2024: Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data
2024: Alkermes' SWOT analysis: undervalued neuro-innovator stock faces pivotal phase
2025: 3 Biopharma Names I Am Buying After Avadel's Buyout | Seeking Alpha
2025: Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment
Organization & Developments: Alkermes (Archives 2008-2017)
Jumps
*Key People: Alkermes
Finance & Acquisitions: Alkermes